STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	In the abstract section in	in the abstract section
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	On the abstract section in	in the abstract section
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	On page5-6, line 56-92	In introduction section
Objectives	3	State specific objectives, including any prespecified hypotheses	On page6, line 89-92	In introduction section
Methods				
Study design	4	Present key elements of study design early in the paper	On page 7, line 95-98	In Methods section
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	On page 7, line 95-98	In Methods section subheading"Patients
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	On page 7, line 95-109	In Methods section subheading"patients selection" on Page 7
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	NA, case match was not designed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	NA, case match was not designed	NA
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	On page 7-8, line 112-122; page 9, line 136-146	In Methods section subheading"Radiological
Bias	9	Describe any efforts to address potential sources of bias	On page 9,line 149-154	In Methods section
Study size	10	Explain how the study size was arrived at	On page 7, line 95-98	In Methods section
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	On page 8, line 125-133	In Methods section subheading"Patients

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	On page 9-10, line	In Methods section
		(b) Describe any methods used to examine subgroups and interactions	On page 9-10, line	In Methods section
		(c) Explain how missing data were addressed	No missing data,	No missing data,
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	NA, follow-up is not required in present study	NA, follow-up is not required in present study
		(e) Describe any sensitivity analyses	On page 9, line 149-154	In Methods section
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	On page 11, line 172-178	In Results section subheading"Demographic
		(b) Give reasons for non-participation at each stage	On page 11, line 172-178,	In Results section
		(c) Consider use of a flow diagram	NA	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	On page 11, line 172-178	In Results section subheading"Demographic
		(b) Indicate number of participants with missing data for each variable of interest	NA, follow-up is not	NA, follow-up is not
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	NA, follow-up is not	NA, follow-up is not
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	On page 11, line 172-178	In Results section
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	NA, present study is not a	NA, present study is not a
		Cross-sectional study—Report numbers of outcome events or summary measures	NA, present study is not a	NA, present study is not a
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	On page 11, line 172-192	In Results section subheading"Demographic
		(b) Report category boundaries when continuous variables were categorized	On page 8, line 125-133,	In Methods section
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	On page 12-13, line	In Results section
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	On page 12, line 193-199	In Results section
Discussion				
Key results	18	Summarise key results with reference to study objectives	On page 14, line 224-232	In Discussion section in
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	On page 17, line 285-293	In Discussion section in page 17

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	In page 14-17, line 224-301	In Discussion section in page 14-17
Generalisability	21	Discuss the generalisability (external validity) of the study results		
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	On page 2, line 23-26	On page 2

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/qims-22-222.
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.